JP2009525764A5 - - Google Patents

Download PDF

Info

Publication number
JP2009525764A5
JP2009525764A5 JP2008554523A JP2008554523A JP2009525764A5 JP 2009525764 A5 JP2009525764 A5 JP 2009525764A5 JP 2008554523 A JP2008554523 A JP 2008554523A JP 2008554523 A JP2008554523 A JP 2008554523A JP 2009525764 A5 JP2009525764 A5 JP 2009525764A5
Authority
JP
Japan
Prior art keywords
antibody
composition
cancer
fgf19
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008554523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009525764A (ja
JP5209505B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/061936 external-priority patent/WO2007136893A2/en
Publication of JP2009525764A publication Critical patent/JP2009525764A/ja
Publication of JP2009525764A5 publication Critical patent/JP2009525764A5/ja
Application granted granted Critical
Publication of JP5209505B2 publication Critical patent/JP5209505B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008554523A 2006-02-10 2007-02-09 抗ｆｇｆ１９抗体およびその使用方法 Expired - Fee Related JP5209505B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US77231006P 2006-02-10 2006-02-10
US60/772,310 2006-02-10
US78060806P 2006-03-09 2006-03-09
US60/780,608 2006-03-09
US88586607P 2007-01-19 2007-01-19
US60/885,866 2007-01-19
PCT/US2007/061936 WO2007136893A2 (en) 2006-02-10 2007-02-09 Anti-fgf19 antibodies and methods using same

Publications (3)

Publication Number Publication Date
JP2009525764A JP2009525764A (ja) 2009-07-16
JP2009525764A5 true JP2009525764A5 (enExample) 2010-03-18
JP5209505B2 JP5209505B2 (ja) 2013-06-12

Family

ID=38723925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008554523A Expired - Fee Related JP5209505B2 (ja) 2006-02-10 2007-02-09 抗ｆｇｆ１９抗体およびその使用方法

Country Status (10)

Country Link
US (4) US7678373B2 (enExample)
EP (1) EP1989230B1 (enExample)
JP (1) JP5209505B2 (enExample)
AR (1) AR059432A1 (enExample)
AU (1) AU2007254005B2 (enExample)
CA (1) CA2637988A1 (enExample)
ES (1) ES2582652T3 (enExample)
NZ (1) NZ569957A (enExample)
TW (1) TWI388568B (enExample)
WO (1) WO2007136893A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
JP5209505B2 (ja) * 2006-02-10 2013-06-12 ジェネンテック， インコーポレイテッド 抗ｆｇｆ１９抗体およびその使用方法
JP5328018B2 (ja) * 2006-06-05 2013-10-30 国立大学法人広島大学 抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
TW201446265A (zh) * 2007-04-02 2014-12-16 建南德克公司 克羅梭（ｋｌｏｔｈｏ）ｂｅｔａ調節劑之用途
EP2188310B1 (en) 2007-08-03 2017-02-08 Genentech, Inc. Humanized anti-fgf19 antagonists and methods using same
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
US20090226459A1 (en) * 2008-01-29 2009-09-10 Cold Spring Harbor Laboratory Role of fgf-19 in cancer diagnosis and treatment
JP2011519851A (ja) * 2008-04-30 2011-07-14 ウントレサーチ・エービー エストロゲンレセプターα活性の修復
KR20110028450A (ko) * 2008-06-16 2011-03-18 이뮤노젠 아이엔씨 새로운 상승 효과
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
WO2010006214A1 (en) * 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
CN102171343B (zh) 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
CA2777717C (en) * 2009-10-15 2021-05-25 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
PT2498799T (pt) 2009-11-13 2016-11-04 Five Prime Therapeutics Inc Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
JP4881428B2 (ja) * 2009-12-25 2012-02-22 株式会社東芝 電子機器
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
AU2012225310B2 (en) 2011-03-09 2017-08-03 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
US20140294820A1 (en) * 2011-06-24 2014-10-02 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
WO2013074492A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. Methods of treating cancer
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
RU2014133547A (ru) * 2012-01-18 2016-03-10 Дженентек, Инк. Способы применения модуляторов fgf19
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
IL282953B2 (en) 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for the treatment of claudin-expressing cancers
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
US10793626B2 (en) * 2013-12-20 2020-10-06 Angiobiomed Gmbh Adrenomedullin binder for use in therapy of cancer
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
SG11201702757YA (en) * 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
EP3274344B1 (en) 2015-03-25 2019-04-24 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors
US10995143B2 (en) 2016-02-10 2021-05-04 Daiichi Sankyo Europe Gmbh Combination of human anti-FGFR4 antibody and Sorafenib
WO2017200016A1 (ja) * 2016-05-17 2017-11-23 公益財団法人がん研究会 Ｅｇｆｒ－ｔｋｉ耐性を獲得した肺癌の治療薬
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
JP7394623B2 (ja) 2016-11-02 2023-12-08 ノバルティス アーゲー Ｆｇｆｒ４インヒビターおよび胆汁酸捕捉薬の組合せ
CN110054700A (zh) * 2018-01-18 2019-07-26 分子克隆研究室有限公司 长效治疗性融合蛋白
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
CN109251983B (zh) * 2018-08-15 2022-03-25 深圳市罗湖区人民医院 Frs2基因的拷贝数扩增及其应用、检测拷贝数扩增的特异性引物对
CN119033684A (zh) 2018-10-29 2024-11-29 豪夫迈·罗氏有限公司 抗体制剂
WO2020156539A1 (en) * 2019-02-02 2020-08-06 Huahui Health Ltd. Anti-fgf19 antibodies
PT3865155T (pt) * 2020-02-13 2023-01-02 Orano Med Processo para modificação específica de local de um anticorpo
CN116726005B (zh) * 2022-03-03 2026-02-13 上海市第六人民医院 一种治疗运动损伤的药物及筛选方法和应用
AU2023272443A1 (en) 2022-05-19 2024-10-31 Tyra Biosciences, Inc. Therapies with ppar agonists and fgfr4 inhibitors
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment
WO2026143225A1 (en) 2024-12-27 2026-07-02 Tyra Biosciences, Inc. Therapies with ppar agonists and fgfr3 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US20020042367A1 (en) 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20020012961A1 (en) 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
US20050026832A1 (en) 1997-11-25 2005-02-03 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
EP1032668B1 (en) 1997-11-25 2008-05-28 Genentech, Inc. Fibroblast growth factor-19
US20040126852A1 (en) 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US20020155543A1 (en) 1997-11-25 2002-10-24 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
CA2384089A1 (en) 1999-09-08 2001-03-15 Genentech, Inc. Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
AU2001252940A1 (en) 2000-03-22 2001-10-03 Amgen Inc. Fibroblast growth factor receptor-like molecules and uses thereof
US20030143539A1 (en) 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
CA2459219A1 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20030157082A1 (en) 2002-01-31 2003-08-21 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
AU2003243400B2 (en) * 2002-06-07 2009-10-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20050198642A1 (en) * 2004-03-04 2005-09-08 International Business Machines Corporation Mechanism for assigning home nodes to newly created threads
US7837626B2 (en) * 2005-08-05 2010-11-23 Siemens Medical Solutions Usa, Inc. Contrast agent manipulation with medical ultrasound imaging
JP5209505B2 (ja) 2006-02-10 2013-06-12 ジェネンテック， インコーポレイテッド 抗ｆｇｆ１９抗体およびその使用方法

Similar Documents

Publication Publication Date Title
JP2021524268A5 (enExample)
JP2021524267A5 (enExample)
JP2021514664A5 (enExample)
JP2021508469A5 (enExample)
JP2021526022A5 (enExample)
JP2021511058A5 (enExample)
JP2010531140A5 (enExample)
JP2017529838A5 (enExample)
JP2010509931A5 (enExample)
JP2020517249A5 (enExample)
TW202126693A (zh) 標靶bcma的抗體、雙專一性抗體及其用途
JP2010532982A5 (enExample)
JP2018519364A5 (enExample)
HRP20140244T1 (hr) Sastavi i metode za inhibiranje pdgfrbeta i vegf-a
HRP20131107T1 (hr) Anti-notch1 nrr-protutijela i postupak njihove uporabe
JP2009545325A5 (enExample)
JP2017522861A5 (enExample)
JP2008529489A5 (enExample)
JP2013538553A5 (enExample)
JP2017514461A5 (enExample)
JP2008500815A5 (enExample)
RU2013102225A (ru) АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2015517300A5 (enExample)
JP2011514150A5 (enExample)
WO2011103700A1 (zh) 一种全人源抗her2单克隆抗体、其制备方法及用途